Nalu Medical kicks-off ‘Engineered to be More™’ with new product releases and software upgrade to provide more therapy options and support for its patients and physicians
CARLSBAD, Calif. (PRWEB) October 20, 2021
Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of intractable chronic pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, launches its ‘Engineered to be More’ branding campaign. The campaign highlights the award-winning engineering design of its Nalu micro-Implantable Pulse Generator (mIPG) and how the Nalu neurostimulation system is engineered to address major unmet needs in the management of intractable chronic pain and provide a differentiated value proposition for patients and physicians.
To kickoff this campaign, Nalu has released three products and a software upgrade to support patients across different stages of the Nalu neurostimulation experience:
- Dual 4 mIPG & 4-contact trial lead – a new IPG and lead configuration for use in Peripheral Nerve Stimulation (PNS) applications
- “Mauna Kea” software upgrade – the latest Nalu system software upgrade which expands programmable stimulation parameter ranges and introduces additional programming efficiencies
- Nalu Patient Care Portal – an online, cloud-based software platform designed to engage Nalu patients with their multidisciplinary care teams from the time they are introduced to neurostimulation through post-surgery and beyond, living their lives with a Nalu implant
“As we build upon our foundational Nalu Neurostimulation System, we remain focused on a simple premise, enabling the management of chronic intractable pain while minimizing interference with the patient’s life,” said Earl Fender, President and CEO of Nalu Medical, Inc. “Each Nalu product is engineered to be more livable, durable and adaptable for our patients, so we are able to meet their needs at every stage and step of their pain management journey.”
The Nalu Neurostimulation System features a micro-Implantable Pulse Generator (mIPG) which is powered wirelessly by a wearable, external Nalu Therapy Disc. The external power source offers a distinct benefit over IPGs with implanted batteries, which require battery replacement surgeries over time. Additionally, the Nalu software controlling the mIPG can be non-invasively upgraded so patients can benefit from future FDA-authorized therapy options and advancements without additional surgical interventions.
The Dual 4 mIPG builds on the original Nalu mIPG technology and consists of dual connectors designed to accommodate two 4-contact stimulation leads. This new design further expands the adaptability of the Nalu Neurostimulation System for PNS patients. The Dual 4 mIPG allows physicians to address nerve targets with two individual leads, providing increased treatment flexibility with the positional stability of tined leads. To compliment the Dual 4 mIPG, two types of 4-contact PNS leads are available; a 4-contact tined lead for implants and a recently released 4-contact trial lead.
“The ability to have full, independent control of stimulation programs for multiple leads when addressing separate nerve targets is critical in many PNS applications,” said Dr. Amitabh Gulati, President of World Academy of Pain Medicine (WAPMU). “For example, neuropathic pain of the shoulder varies from patient to patient and may necessitate differing therapy applications to both the suprascapular and axillary nerves. The opportunity to address this for my patients in a single, powerful stimulator like the Dual 4 mIPG is significant.”
Like a smartphone operating system, the Nalu Neurostimulation System software can be upgraded allowing existing patients’ full access to future software innovation and additional capabilities as they are authorized by the FDA. This latest software upgrade, known as “Mauna Kea,” expands stimulation dosing parameter ranges and programming configurations for both PNS and SCS indications. The upgrade also introduces additional performance and display improvements to the clinical programmer intended for use by health care providers.
Nalu’s Patient Care Portal allows for monitoring and addressing the needs of patients at each stage of their Nalu Neurostimulation experience. The cloud-based Patient Care Portal experience begins during the patient’s Nalu Wear Experience & trial period as the patient completes a series of surveys to initiate a tailored post-implantation pain management treatment plan controlled and determined by the healthcare team. After the implantation procedure, pain management treatment plans are personalized further by the healthcare team based on regular engagements with the Patient through the Portal as they resume their routine daily activities post-surgery.
“Being able to track a patient’s progress and recovery is critical, especially with pain management patients,” said Dr. Sean Li of Premier Pain Centers in New Jersey. “The Nalu Patient Care Portal is designed to deliver valuable and usable data for my care team while also providing an effortless and engaging environment for my patients.”
About Nalu Medical
We are a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. Our Nalu neurostimulation system, or Nalu system, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain. We designed our Nalu system to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.
About the Nalu Neurostimulation System
Our proprietary Nalu system consists of a fully-featured, battery-free, miniaturized IPG (Implantable Pulse Generator), which is powered by an externally worn Therapy Disc and controlled through a smartphone based remote control app. Our proprietary nPower microchip provides a broad menu of programmable therapy options. The Nalu Neurostimulation System is currently FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation indications. To learn more, visit http://nalumed.com.
Indications for Use
Spinal Cord Stimulation – The Nalu Neurostimulation System for SCS is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.
Peripheral Nerve Stimulation – The Nalu Neurostimulation System for PNS is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.
Nalu, the Nalu logo, nPower the ‘engineered to be more’ tagline are trademarks of Nalu Medical, Inc.